Adults: Recommended Dose: 400 mg once daily for all indications. The tablets are swallowed whole with a glass of water. They can be taken independent of food intake.
Duration of Treatment: The duration of treatment should be determined by the severity of the indication or clinical response. The following general recommendations for the treatment of upper and lower respiratory tract infections are made: Acute Exacerbation of Chronic Bronchitis: 5 days.
Community-Acquired Pneumonia: 10 days for the tablet and 7-14 days for the infusion solution.
Acute Sinusitis: 7 days.
Uncomplicated Skin and Skin Structure Infections: 7 days.
Uncomplicated Pelvic Inflammatory Disease: 14 days.
Complicated Skin and Skin Structure Infections for Sequential Therapy (IV followed by Oral Therapy): 7-21 days.
Complicated Intra-Abdominal Infections for Sequential Therapy (IV followed by Oral Therapy): 5-14 days.
Infuse over a period of 60 min. The recommended duration of treatment for the indication being treated should not be exceeded. Avelox 400-mg tablets have been studied in clinical trials for up to 21 days (in complicated skin and skin structure infections).
Elderly: No dosage adjustment is required in the elderly.
Inter-Ethnic Differences: No dosage adjustment is required in ethnic groups.
Hepatic Impairment: No dosage adjustment is required in patients with impaired liver function (see Precautions).
Renal Impairment: No dose adjustment is required in patients with any degree of renal impairment (including creatinine clearance ≤30 mL/min/1.73 m2) and in patients on chronic dialysis ie, hemodialysis and continuous ambulatory peritoneal dialysis.